Close menu

November 22nd, 2023 | 07:00 CET

Bayer, Cardiol Therapeutics, K+S AG - Clear opportunities after bottoming out

  • Biotechnology
  • Pharma
Photo credits:

Shareholders of the chemical and pharmaceutical company Bayer suffered a black Monday following the discontinuation of a Phase III trial. As a result, Bayer shares fell to their lowest level since 2009. In contrast, there is optimism among other companies for a strong rebound. The biotech sector, in particular, seems to have bottomed out. There is a long-term opportunity for outperformance here, especially with second-tier companies.

time to read: 4 minutes | Author: Stefan Feulner

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    Bayer AG - Bye Bye Bayer

    It was one of the darkest days in the recent history of the Leverkusen-based company. With a temporary decline of up to 20%, Bayer shares not only tore through all support lines but also marked their lowest price since March 2009 at EUR 32.60.

    One reason for the sharp sell-off was that a US jury ordered the chemical giant to pay more than USD 1.5 billion to three former users of the weedkiller in a glyphosate lawsuit.

    "This judgment will not stand, and we will definitely appeal against it," Bayer announced over the weekend. The Company stated that the amount of punitive damages alone violates the US Constitution. "In contrast to previous proceedings, the courts in the recent cases have improperly allowed the plaintiffs to misrepresent regulatory and scientific facts," it continued.

    The second shock announcement followed on Sunday evening. Accordingly, the Company announced the premature discontinuation of a Phase III trial investigating asundexian versus apixaban in patients with atrial fibrillation and stroke risk. However, the decision was not made by the management of the DAX Group but was based on the recommendation of the Independent Data Monitoring Committee (IDMC) as part of the ongoing study monitoring. Initially, the long-term plan was for asundexian to become the successor to the blockbuster drug Xarelto.

    Due to the setback, the US bank JP Morgan continued to rate the chemical and pharmaceutical giant as "Neutral" and reiterated its target price of EUR 47. However, analyst Richard Vosser said that the discontinuation of the study was a bitter disappointment. As a result, the revenue potential of the drug, which was previously included at EUR 11.70 in the valuation model, is now reduced.

    Cardiol Therapeutics - The 600% Opportunity

    A specialist in the research and clinical development of innovative therapies for the treatment of cardiovascular diseases is valued at just CAD 77.76 million. Compared to the peer group, their undervaluation should catch the eye of any experienced investor. This is especially noteworthy considering that as of the end of September, the Canadian company had cash reserves of CAD 40.5 million, sufficient to finance the development of various programs until 2026.

    Even better, their two clinical programs are progressing as planned or ahead of schedule. Earlier this month, Cardiol Therapeutics announced that recruitment for their Phase II MAvERIC-Pilot study for the treatment of recurrent pericarditis has exceeded 50% enrollment. The MAvERIC-Pilot study is enrolling 25 patients at various medical research centers in the United States that specialize in the treatment of pericarditis. The primary efficacy endpoint is the change in patient-reported pericarditis pain measured using an 11-point numeric rating scale from baseline to eight weeks.

    In addition, the life sciences company announced study results showing that an experimental model of pericarditis induces a so-called mesothelial to mesenchymal transition (MMT), a transition from mesothelial cell to mesenchymal cell and that this process is inhibited by cannabidiol treatment, the active pharmaceutical ingredient in CardiolRx™. The Company's international research collaborators submitted a summary of these results to the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, which took place in the Serbian capital, Belgrade.

    From a chart perspective, everything is also moving in the right direction. After the share price reached a new yearly high of USD 1.24 at the beginning of August, following a strong upward movement, the share price formed a bottom around USD 0.75. Shares of Cardiol are currently trading at USD 0.87, on the verge of testing the downward trend established in August. A breakthrough to the upside would generate short-term price potential up to the previous yearly high. The upward trend is supported by the MACD and RSI indicators forming several positive divergences, which can be seen as a very bullish sign. Speaking of price targets! In their recent company update (November 15), the analysts at Canaccord Genuity maintained their price target of USD 6.00, representing a price opportunity of almost 600% return from current levels.

    K+S AG - Analysts skeptical

    The environment remains challenging; however, the third quarter may have heralded a turnaround for the supplier of potash and magnesium-based products for agricultural and industrial applications. The fact that potash prices in the critical Brazilian market are stabilizing compared to the first half of the year is positive. Due to the weak overall market, K+S had to lower its annual profit target in June due to weak potash prices. This was confirmed following the announcement of the figures for the third quarter.

    Accordingly, the Company led by CEO Dr. Burkhard Lohr continues to expect EBITDA of between EUR 600 and 800 million for the full year 2023. K+S AG is thus far behind the record year of 2022, in which EBITDA of EUR 2.4 billion was posted. Adjusted cash flow is expected to be in a broad range between EUR 300 million and EUR 450 million, compared to the previous year's figure of EUR 932 million.

    Following the publication of the figures, several analyst firms came forward. The Swiss bank UBS reiterated its "Sell" rating with a target price of EUR 13. On the other hand, analyst firm Jefferies downgraded K+S from "Buy" to "Hold". The price target was reduced from EUR 25 to the current level of EUR 15. Analyst Chris Counihan significantly reduced his estimates for 2024, which puts him 20% below analysts' consensus estimates for operating earnings.

    On December 5, K+S AG will present at the 9th IIF - International Investment Forum. You can register here

    Bayer shareholders experienced a black Monday. In contrast, K+S AG delivered solid quarterly results. Nevertheless, the analyst consensus remains skeptical. Financial experts, on the other hand, view the development of the biotech company Cardiol Therapeutics much more positively.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author

    Related comments:

    Commented by André Will-Laudien on February 20th, 2024 | 07:30 CET

    Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?

    • Biotechnology
    • Pharma
    • Innovations

    It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.


    Commented by André Will-Laudien on February 16th, 2024 | 07:00 CET

    MorphoSys and Cardiol Therapeutics in upward mode, while Bayer and Pfizer are in slow mode

    • Biotechnology
    • Pharma

    The biotech sector has made a very differentiated start to the new year. While the old favorites are barely moving, the second-line stocks MorphoSys and Cardiol Therapeutics are making a real splash. At Bayer, the bad news just won't go away, and despite a successful major takeover, Pfizer has not yet found its forward gear. After a rally of almost 15% in December, the Nasdaq Biotechnology Index (NBI) has taken a pause in the current year. Now, everyone is waiting for the first interest rate cut by central banks. Inflation is already falling, and the negative economic data for the Eurozone is increasing. The ECB would normally be in demand. What should investors urgently keep an eye on?


    Commented by Fabian Lorenz on February 14th, 2024 | 07:00 CET

    Plug Power, Bayer, Defense Metals: Shares in panic mode

    • Mining
    • RareEarths
    • Hydrogen
    • Pharma

    Is everything not so bad at Plug Power, after all? In January, the hydrogen specialist triggered panic among investors with an announced capital increase. Now, the CEO is suddenly rowing back. So, should one buy the stock now? One analyst advises caution. Bayer shareholders are also in panic mode. The downward trend of the share simply cannot find a bottom. Even at this level, analysts are cautious. Defense Metals, on the other hand, is benefiting from panic - because this concerns the supply of rare earths. The dependence on China is enormous. Defense Metals aims to change this with its rare earth project in Canada. The Company CEO expressed confidence in an interview, stating that an important agreement has been reached with the local population, and important dates are on the horizon.